PARP1 interacts with STAT3 and retains active phosphorylated-STAT3 in nucleus during pathological myocardial hypertrophy
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 474, 137-150
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81673433, 81473205)
- Major Project of Guangdong Province (2015B020232009, 2014B020210003, 2013B090700010)
- Major Project of Platform Construction Education Department of Guangdong Province (2014GKPT002)
This publication has 40 references indexed in Scilit:
- PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma modelAllergy, 2011
- PARP-14 Functions as a Transcriptional Switch for Stat6-dependent Gene ActivationJournal of Biological Chemistry, 2011
- Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?☆Pharmacological Research, 2010
- Deciphering STAT3 Signaling in the Heart: Plasticity and Vascular InflammationCongestive Heart Failure, 2010
- JAK redux: a second look at the regulation and role of JAKs in the heartAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophyCardiovascular Research, 2009
- Regulation of Transcription Factor NFAT by ADP-RibosylationMolecular and Cellular Biology, 2008
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitorThe EMBO Journal, 2008
- Role of Poly(ADP‐ribose) polymerase 1 (PARP‐1) in Cardiovascular Diseases: The Therapeutic Potential of PARP InhibitorsCardiovascular Drug Reviews, 2007
- What does Stat3 do?Journal of Clinical Investigation, 2002